Xiamen, 28 January 2019 – Amoy Diagnostics Co., LTD., a leading company focusing on molecular diagnostics for precision oncology, and Sanomics Limited, a pioneering company in providing genomics tests in Hong Kong and all over the world, today announced a collaboration partnership to deliver multi-gene tests for screening patients who will be benefit from targeted therapy in Hong Kong and Macau.
Sanomics will launch service of “OncoSnap NonetTM” based on technical transfer of AmoyDx’s strategic product “AmoyDx® Multi-Gene Mutations Detection Kit”, the world’s first 9 genes qPCR panel kit, which was approved by CFDA (now NMPA, National Medical Products Administration) on 24 August 2018. This test is based on completely independent intellectual property rights of ADx-ARMS technology.
“OncoSnap NonetTM” screens for 9 genes in tumor tissue samples, intending to aid physicians to identify multi-genetic biomarkers for potential treatment options for primary diagnosed non-small-cell lung cancer patients.
“Delivering fast, accurate and affordable molecular diagnostics that can enable easy, quick and efficient diagnosis exactly conforms to our principal “Patient First”, that’s why I am excited to collaborate with Amoy Diagnostics, putting patients’ needs as our priority. We aim to provide easy and convenient access to our services and help doctors to decide personalized cancer solutions for patients,” said Professor Tony Mok, shareholder of Sanomics Limited and world famous lung cancer specialist.
Media contacts
Amoy Diagnostics Co., LTD.
Paul HUANG
Tel: (+86) 592 6806058
Email: paulhuang@amoydx.com
Sanomics Limited
Stanley SY
Tel: (852)-6202-6790
Email: stanley.sy@sanomics.com